AVAI
SPRO icon

Atlas Venture Associates IX’s Spero Therapeutics SPRO Stock Holding History

Atlas Venture Associates IX’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$1.64M Hold
1,353,303
– – 13.93% 3
2023
Q2 		$1.96M Sell
1,353,303
-23,665
-2% -$40.5K 10.74% 3
2023
Q1 		$2M Hold
1,376,968
– – 9.37% 3
2022
Q4 		$2.38M Hold
1,376,968
– – 11.85% 3
2022
Q3 		$2.75M Hold
1,376,968
– – 8.16% 3
2022
Q2 		$1.02M Hold
1,376,968
– – 2.32% 6
2022
Q1 		$12M Hold
1,376,968
– – 11.02% 2
2021
Q4 		$22M Hold
1,376,968
– – 9.62% 2
2021
Q3 		$25.4M Hold
1,376,968
– – 8.43% 2
2021
Q2 		$19.2M Hold
1,376,968
– – 3.38% 3
2021
Q1 		$20.3M Hold
1,376,968
– – 3.41% 4
2020
Q4 		$26.7M Hold
1,376,968
– – 4.23% 4
2020
Q3 		$15.4M Hold
1,376,968
– – 15.9% 3
2020
Q2 		$18.6M Hold
1,376,968
– – 19.92% 3
2020
Q1 		$11.1M Hold
1,376,968
– – 23.53% 2
2019
Q4 		$13.2M Hold
1,376,968
– – 23.08% 2
2019
Q3 		$14.6M Hold
1,376,968
– – 24.02% 2
2019
Q2 		$15.8M Hold
1,376,968
– – 16.95% 3
2019
Q1 		$17.6M Hold
1,376,968
– – 16.57% 4
2018
Q4 		$8.47M Hold
1,376,968
– – 9.75% 5
2018
Q3 		$14.5M Hold
1,376,968
– – 7.66% 5
2018
Q2 		$20.2M Hold
1,376,968
– – 8.89% 5
2018
Q1 		$19.6M Hold
1,376,968
– – 14.83% 4
2017
Q4 		$16.2M Buy
+1,376,968
New +$16.9M 14.33% 3

Other funds holding SPRO

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Atlas Venture Associates IX's SPRO Position: Q3 2023 in Review

Atlas Venture Associates IX held its Spero Therapeutics (SPRO) position steady in Q3 2023 at 1,353,303 shares worth $1.64M. The position accounts for 13.93% of the portfolio, ranked #3.

Atlas Venture Associates IX first reported a position in SPRO in Q4 2017 and has held it in 24 quarters since. The position peaked at $26.7M in Q4 2020. 54 funds tracked by Wall St. Rank hold SPRO as of Q3 2023.

  • Atlas Venture Associates IX held 1,353,303 shares of Spero Therapeutics worth $1.64M as of Q3 2023.
  • Atlas Venture Associates IX left its Spero Therapeutics share count unchanged in Q3 2023.
  • Spero Therapeutics made up 13.93% of Atlas Venture Associates IX's portfolio in Q3 2023, its #3 holding.
  • Atlas Venture Associates IX first reported a position in Spero Therapeutics in Q4 2017 and has held it in 24 quarters since.
  • Atlas Venture Associates IX's Spero Therapeutics position peaked at $26.7M in Q4 2020.
  • 54 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2023.

Based on Atlas Venture Associates IX's 13F filing for Q3 2023, filed 13 Nov 2023.